Organon & Co. (NYSE:OGN) Receives $18.00 Average Target Price from Analysts

Shares of Organon & Co. (NYSE:OGN) have earned an average rating of “Moderate Buy” from the six analysts that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $18.00.

OGN has been the subject of several recent analyst reports. Evercore ISI lowered Organon & Co. from an “outperform” rating to an “inline” rating in a research note on Friday, May 2nd. BNP Paribas upgraded Organon & Co. to a “strong-buy” rating in a research note on Thursday, May 22nd. Piper Sandler dropped their price objective on Organon & Co. from $24.00 to $18.00 and set an “overweight” rating for the company in a research note on Thursday, May 15th. Finally, Morgan Stanley dropped their price objective on Organon & Co. from $15.00 to $10.00 and set an “equal weight” rating for the company in a research note on Monday, May 5th.

Insider Buying and Selling

In other Organon & Co. news, VP Daniel Karp acquired 3,500 shares of the business’s stock in a transaction dated Tuesday, May 6th. The shares were acquired at an average price of $8.24 per share, for a total transaction of $28,840.00. Following the acquisition, the vice president directly owned 46,669 shares of the company’s stock, valued at approximately $384,552.56. This trade represents a 8.11% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Kevin Ali bought 34,000 shares of the company’s stock in a transaction that occurred on Monday, May 5th. The stock was purchased at an average cost of $8.80 per share, for a total transaction of $299,200.00. Following the transaction, the chief executive officer owned 282,731 shares in the company, valued at $2,488,032.80. The trade was a 13.67% increase in their position. The disclosure for this purchase can be found here. Insiders have purchased a total of 102,345 shares of company stock valued at $902,430 over the last 90 days. 1.96% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in OGN. Hsbc Holdings PLC raised its position in Organon & Co. by 13.9% in the 4th quarter. Hsbc Holdings PLC now owns 13,922 shares of the company’s stock worth $208,000 after buying an additional 1,703 shares during the last quarter. Wells Fargo & Company MN increased its holdings in shares of Organon & Co. by 28.6% in the 4th quarter. Wells Fargo & Company MN now owns 262,746 shares of the company’s stock valued at $3,920,000 after acquiring an additional 58,378 shares during the last quarter. NBC Securities Inc. increased its holdings in shares of Organon & Co. by 111,262.5% in the 1st quarter. NBC Securities Inc. now owns 8,909 shares of the company’s stock valued at $132,000 after acquiring an additional 8,901 shares during the last quarter. Wellington Management Group LLP increased its holdings in shares of Organon & Co. by 44.2% in the 4th quarter. Wellington Management Group LLP now owns 32,966 shares of the company’s stock valued at $492,000 after acquiring an additional 10,108 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of Organon & Co. in the 4th quarter valued at approximately $4,194,000. Institutional investors and hedge funds own 77.43% of the company’s stock.

Organon & Co. Stock Up 0.8%

Shares of OGN stock opened at $9.64 on Monday. Organon & Co. has a 12 month low of $8.01 and a 12 month high of $23.10. The firm has a market cap of $2.50 billion, a PE ratio of 3.35, a price-to-earnings-growth ratio of 0.99 and a beta of 0.60. The stock has a 50 day moving average of $9.50 and a 200-day moving average of $12.60. The company has a quick ratio of 1.15, a current ratio of 1.67 and a debt-to-equity ratio of 16.49.

Organon & Co. (NYSE:OGN) last issued its earnings results on Thursday, May 1st. The company reported $1.02 EPS for the quarter, beating analysts’ consensus estimates of $0.89 by $0.13. The business had revenue of $1.51 billion during the quarter, compared to analyst estimates of $1.53 billion. Organon & Co. had a return on equity of 227.43% and a net margin of 11.92%. Organon & Co.’s revenue was down 6.7% on a year-over-year basis. During the same period in the prior year, the company posted $1.22 earnings per share. On average, equities analysts predict that Organon & Co. will post 3.68 EPS for the current year.

Organon & Co. Cuts Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, June 12th. Shareholders of record on Monday, May 12th were issued a dividend of $0.02 per share. This represents a $0.08 dividend on an annualized basis and a yield of 0.83%. The ex-dividend date was Monday, May 12th. Organon & Co.’s dividend payout ratio (DPR) is currently 2.78%.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.